SVP, Clinical Drug Development
Generate Biomedicines
New York, NY, United States
Dinesh de Alwis has over 25 years of global experience in the pharmaceutical industry, working with large and small molecules from discovery to regulatory filing and post marketing.
He is currently SVP,Clinical Drug Development at Generate Biomedicines and has responsibility for Clinical Pharmacology, Clinical Biomarkers, Biometrics and Toxicology and is involved in providing clinical design and clinical pharmacology input and analysis for the
COVID-19 program. He was previously an Associate Vice President in Quantitative Pharmacology within Oncology Early Development at Merck. During the 10 years at Merck, Dinesh played a significant part in the early oncology dose finding and registration of Keytruda for Melanoma, NSCLC and multiple other indications including the first tumor agnostic biomarker approval for cancer. Dinesh is considered a expert in his field and has extensive drug development and regulatory experience with multiple modalities including mAb’s. Before Merck, Dinesh held several leadership and scientific roles at Eli Lilly and Company for 15 years and led the PK/PD Group in the UK from preclinical to late development across several therapeutic areas.
Dr de Alwis has published over 50 peer reviewed papers and received his PhD from the University of Manchester (1997), UK in the field of Population PK/PD.
Disclosure(s): Generate Biomedicines: Stocks/Bonds (Private Company)
Thursday, October 17, 2024
10:54 AM – 11:06 AM US PT